Why the Materials in Your Wearable Medical Device Trigger a Biocompatibility Review


There's a version of this problem that shows up regularly in device development. An engineer has been building wearable technology for years — fitness trackers, smartwatches, consumer health monitors. The materials are familiar. Silicone, TPU, stainless steel hardware, an acrylic adhesive. Standard stuff.
Then the device gets a clinical indication, or starts collecting data that feeds a diagnostic algorithm, or pairs with a drug delivery function. Now it's a medical device. And suddenly, every material decision that felt routine is the subject of a formal biocompatibility review.
The materials didn't change. But what's required of them did.
Here's what actually happens when those materials go through the ISO 10993-1:2025 biological evaluation process and why the chemistry you've been ignoring matters.
Every Material in Patient Contact Goes Into the Evaluation
Under ISO 10993-1:2025, the biological evaluation of a medical device starts with a full characterization of everything in direct or indirect contact with the patient. That means every material, not just the housing or the skin-contact layer. The standard specifically requires consideration of:
Materials of construction — all components with direct or indirect patient contact
Manufacturing process impacts — how molding, machining, surface treatments, or sterilization alter material properties or introduce new substances
Intentional additives — catalysts, antioxidants, pigments, surface treatments built into the material
Process contaminants — mold release agents, cleaning agents, cutting fluids, lubricants from the manufacturing environment
Primary packaging — constituents from packaging materials, including adhesives, that can transfer to the device
For a wearable patch, that list typically includes the backing film, the skin-contact adhesive, any hydrogel or membrane layers, colorants in the housing or labeling, the electronic encapsulant, metal contacts or electrodes, and whatever was used to bond, clean, or sterilize the finished assembly. Each one of those is a source of potential patient exposure.
The Materials Most Engineers Underestimate
Adhesives
The adhesive layer in a wearable patch is the material in most direct, sustained contact with the patient's skin. It's also one of the most chemically complex components in the device.
Acrylic adhesives, silicone adhesives, and hydrocolloid adhesives all contain residual monomers, crosslinkers, tackifiers, and plasticizers that can leach under use conditions. For a device worn for days at a time, the question isn't whether migration can occur — it's how much, and whether the quantities that reach the patient are toxicologically acceptable.
Adhesives from the same supplier, sold under the same product name, can have different formulations across production lots. If the formulation changes without notification, the chemical characterization data you built the submission on may no longer reflect what's actually in the device.
Silicones
Medical-grade silicone is widely used in wearable housings, gaskets, and skin-contact components because of its established biocompatibility profile. That history of safe use is real and useful but it applies to the base polymer, not necessarily to the finished part as manufactured.
Silicone components contain residual catalyst (typically platinum or tin), processing aids, and sometimes pigments. Manufacturing processes like compression molding or extrusion introduce heat and pressure that can affect the final surface chemistry. Post-cure steps reduce residuals, but their adequacy needs to be verified, not assumed.
ISO 10993-1:2025 is explicit: manufacturing processes that cause bulk or surface changes in material properties, and intended additives such as catalysts and pigments, are part of the characterization requirement. The base polymer's history of safe use does not automatically extend to the finished component as it comes off the line.
Thermoplastic Polyurethanes (TPUs)
TPUs are common in wearable enclosures, straps, and flexible housings because of their mechanical properties and processability. They're also chemically complex. TPU formulations include isocyanates, chain extenders, and stabilizers — and degradation under UV exposure, body heat, or sweat interaction can generate breakdown products that weren't present in the original chemical characterization.
If a wearable device is worn outdoors, subject to sweat exposure, or used in conditions that differ materially from the extraction conditions in a chemical characterization study, the data may not fully represent patient exposure.
Colorants and Dyes
Colorants in wearable housings, adhesive layers, or printed graphics are often treated as invisible from a biocompatibility standpoint. They're not. The ISO standard specifically identifies pigments as a category of additives that must be considered in the biological evaluation. Certain pigments, particularly some azo dyes and heavy-metal-based colorants, have known toxicological concerns.
If a supplier reformulates a pigment package — something that happens without triggering a formal change notification in many supply chains — the biological evaluation may no longer reflect the device as currently manufactured.
Metal Hardware
Wristband buckles, sensor housings, electrode contacts, and device chassis components that use stainless steel, nickel alloys, or titanium all bring metal ion release into the evaluation. For wristband-style devices with prolonged or long-term skin contact, nickel is a sensitization concern — nickel is one of the most common contact allergens in the general population.
Sensitization under ISO 10993-1:2025 is evaluated for all devices with direct or indirect body contact, regardless of contact duration. That means even a device worn briefly requires sensitization evaluation. For prolonged or long-term devices, it's among the first endpoints addressed in the biological evaluation plan.
What the Evaluation Process Does With This Information
ISO 10993-1:2025 uses a risk-based process, not a fixed testing checklist. Once materials are characterized, the process works as follows:
Identify biological hazards — based on the chemical and physical information gathered, determine which hazard types are relevant. The presence of a known sensitizer, carcinogen, or neurotoxin in any material triggers evaluation of that specific hazard regardless of what the device contact category would otherwise require.
Estimate biological risks — using existing data (toxicological literature, supplier data, prior testing, chemical characterization results), evaluate whether each identified hazard poses an acceptable risk at the patient exposure levels that apply to your device.
Conduct a gap analysis — determine which risks cannot be adequately assessed with available data. The gap analysis is the decision point: if existing information is sufficient, testing is not required. If information is insufficient, additional data must be generated.
Commission testing only where gaps exist — biological testing fills gaps. For intact-skin surface devices at all contact durations, cytotoxicity, sensitization, and irritation are consistently relevant endpoints. Systemic toxicity evaluation applies where constituents can reach systemic circulation at relevant levels.
Why Contact Duration Changes the Equation
ISO 10993-1:2025 defines three exposure duration categories:
Limited — total exposure period of 24 hours or less
Prolonged — more than 24 hours but not more than 30 days
Long-term — more than 30 days
A one-time diagnostic patch worn for a few hours is a limited-contact device. A continuous glucose monitor worn for 10 to 14 days is prolonged. A device intended for indefinite daily use is long-term.
Duration affects the scope of systemic toxicity evaluation and informs the genotoxicity and carcinogenicity assessment. It also changes how leachable levels are calculated for the toxicological risk assessment — a substance present at low concentrations in a device worn for 14 days may reach a meaningfully different cumulative patient exposure than the same substance in a device worn for two hours.
The classification that applies is based on total exposure on a single patient across all uses of the device, not per-session contact.
What This Means for Submission
The chemical characterization and toxicological risk assessment you build for a wearable device needs to account for the actual materials in the finished, manufactured, packaged device — not the materials as specified on paper. Supplier data sheets tell you what the base material is. They don't always tell you what the catalyst loading is, what stabilizer package was used, or what the residual monomer profile looks like after the manufacturing process your contract manufacturer runs.
A well-structured biological evaluation plan for a wearable device identifies those gaps before the submission is built, structures the chemical characterization study to generate data that's actually relevant to patient exposure, and feeds that data into a toxicological risk assessment that an FDA reviewer can follow. When the endpoint conclusions are well-supported by the chemical data, the need for in vivo testing frequently doesn't arise. When they're not, you find out in the deficiency letter.
Expert Biocompatibility Consulting for Wearable Medical Devices
At JL Tox Consulting, we help wearable medical device manufacturers work through the material-level complexity of ISO 10993-1:2025 biological evaluations from the initial characterization through chemical characterization study design and toxicological risk assessment.
Our wearable device biocompatibility services include:
Biological evaluation planning — ISO 10993-1:2025 compliant strategy built for your device's specific materials and contact scenario
Chemical characterization study design — extractables and leachables methodology tailored to wearable materials including adhesives, silicones, TPUs, colorants, and metal components
Toxicological risk assessment — endpoint-by-endpoint TRA documentation for 510(k) and De Novo submissions
510(k)/De Novo biocompatibility package development — integrated documentation from evaluation plan through final biocompatibility summary
Deficiency response — targeted responses to FDA biocompatibility questions
With over a decade of specialized experience in medical device biocompatibility and FDA regulatory submissions, Dr. James Lyons and the JL Tox team provide the toxicological and regulatory expertise needed to move your wearable device through clearance efficiently.
Contact JL Tox Consulting to discuss your wearable device biocompatibility program:
Email: info@JLTox.com
Phone: (877) 899-6568



Comments